Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07171203 · ClinicalTrials.gov registry record · Phase 1
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
A Phase 1 study, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07171203 is a Phase 1 study that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 18 participants.
The verdict
NCT07171203, a Phase 1 study, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn what dose of the drug fampridine can be given safely together with imatinib (Gleevec) in patients with gastrointestinal stromal tumor (GIST) with a DNA mutation in exon 11 of the KIT gene. The main questions this study aims to answer are: * What is the maximum dose of fampridine that can be given safely together with imatinib (Gleevec)? * Is the combination of the two drugs efficacious against the tumor? Participants will: * Take the drugs before tumor surgery (preoperative treatment) for at least 2 months with the option to continue for a longer period of time if treatment seems safe and effective. * Visit the clinic at the scheduled appointments for checkups and tests.
Interventions
- DRUG Imatinib
- DRUG Fampridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-05-13 |
| Est. Completion | 2031-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07171203
The ClinicalTrials.gov registry entry for NCT07171203 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib is the first listed.
NCT07171203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07171203 about?
NCT07171203 is a clinical study titled "Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor". The goal of this clinical trial is to learn what dose of the drug fampridine can be given safely together with imatinib (Gleevec) in patients with gastrointestinal stromal tumor (GIST) with a DNA mutation in exon 11 of the KIT gene. The main questions this study aims to answer are: * What is the m...
What is the current status of trial NCT07171203?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-05-13. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07171203?
The interventions under investigation include: Imatinib (DRUG), Fampridine (DRUG).
Who is sponsoring clinical trial NCT07171203?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.